March 15, 2022 -- Catamaran Bio has expanded its research collaboration with the University of Minnesota to advance transposon engineering for CAR-NK cell therapies. The company also said it secured an exclusive, worldwide license to University of Minnesota's patent rights covering next-generation cell expansion technologies.
The cell expansion technologies under the patent do not require the use of feeder cells; these technologies have the potential to improve the efficiency and decrease the cost of manufacturing CAR-NK cell therapies, the company said.
The collaboration, which is with Branden Moriarity, PhD, of the University of Minnesota, will further optimize the TcBuster transposon system, a next-generation nonviral genetic modification system that has been integrated into Catamaran's TAILWIND platform.
Copyright © 2022 scienceboard.net